The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.
21h
Verywell Health on MSNWhat Happens When You Take Growth Hormone Injections?Growth hormone injections deliver a synthetic growth hormone to the body to treat hormone deficiencies and other health ...
If there was a way to help your dog live longer, most owners would agree: it’s a no-brainer and something you’d proudly invest in. Besides keeping your pup up to date on vaccines, on a healthy diet, ...
4h
Zacks Investment Research on MSNShould You Invest in the First Trust NASDAQ Clean Edge Smart Grid Infrastructure ETF (GRID)?Looking for broad exposure to the Utilities - Infrastructure segment of the equity market? You should consider the First Trust NASDAQ Clean Edge Smart Grid Infrastructure ETF (GRID), a passively ...
The Flamenco Festival celebrates its 20th anniversary with its biggest-ever programme of dance and music across two weeks this summer, from 27 May – 8 June 2025 at Sadler’s Wells Theatre and the ...
Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...
Microglia, the brain's immune cells, usually serve as diligent guardians. They eliminate intruders such as microbes and clear ...
Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g.,�autoimmunity) can cause permanent hair loss, a new study shows. This regimen ...
The mantle of world No.1 in tennis is something every player aspires for, but few ever achieve. When it comes to men's singles, only a handful of names have held the top spot over the past two ...
20h
News-Medical.Net on MSNNew research reveals potential path forward for glioblastoma treatmentGlioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results